FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Ty | pe Response | s) | | | | | | | | | | | | | | |
|--|---|---|---------------------|---|--|------------|----------------------------------|--|---------------------------------------|--|--|--|---|-------------------|-------------------------------|------------------|
| 1. Name and Address of Reporting Person * EVNIN LUKE | | | | | 2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL] | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner | | | | | | |
| | | | 0 | 3. Date of Earliest Transaction (Month/Day/Year) 06/28/2004 | | | | | Office | er (give title belo | ow) | Other (specify | below) | | | |
| BOSTON, MA 02199 | | | | 4. | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | | | | 6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person | | | | | |
| (City | | (State) | (Zip) | | | Tab | ole I - | Non | -Derivative | Securit | ies Acqı | ired, Disp | osed of, or l | Beneficially | Owned | |
| (Instr. 3) Date | | 2. Transaction Date (Month/Day/Ye | Execu ar) any | 2A. Deemed Execution Date, if | | Code | | 4. Securities Acquired (A) Disposed of (D) (Instr. 3, 4 and 5) | | | | Form: Direct (D) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | | | ode | V | Amount | (A) or (D) | Price | | | | (I) (Instr. 4) | (msu. 4) | |
| Common | Stock | | 06/28/2004 | | | 1 | S | | 2,877 <u>(1)</u> | D | \$ 15.83 | 3,333 | ,586 | | I | See Footnote |
| Common | Stock | | 06/28/2004 | | | J | <u>r(3)</u> | | 1,499,98 | 9 D | \$ 0 | 1,833 | ,597 | | I | See Footnote (4) |
| Common Stock | | 06/28/2004 | | | | <u>(5)</u> | | 16,203 | 5) A | \$ 0 | 1,849 | ,800 | | I | See Footnote (6) | |
| Reminder: | Report on a s | separate lir | ne for each class o | | es beneficiall | - | | 1 | Persons who contained in the form dis | no resp n this splays | form ar a curre | e not req | uired to res I OMB con | spond unle | ess | 1474 (9-02) |
| | | | | | ., puts, calls | | | | | | | | 1 | 1 | <u> </u> | |
| Security | 2. Conversion or Exercise Price of Derivative Security | e (Month/Day/Year) any (Month/Day/Y | | on Date, | 4. Transaction Code (Instr. 8) Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | | er tive ties red sed | and Expiration Date (Month/Day/Year) | | Am Une Sec | Citle and count of derlying urities str. 3 and | nut of rlying ities . 3 and Derivative Security (Instr. 5) | | | ive Ownersh (Instr. 4) D) ect | |
| | | | | | Code | V (| (A) | | Date Exercisable | Expira Date | tion Titl | Amount or Number of Shares | | | | |

Reporting Owners

| | Relationships | | | | | |
|---|---------------|--------------|---------|-------|--|--|
| Reporting Owner Name / Address | Director | 10% Owner | Officer | Other | | |
| EVNIN LUKE C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVENUE, 31ST FLOOR BOSTON, MA 02199 | | X | | | | |

| GADICKE ANSBERT C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVENUE, 31ST FLOOR BOSTON, MA 02199 | | X | | |
|--|--|---|--|--|
|--|--|---|--|--|

Signatures

| /s/ Luke Evnin | 06/30/2004 | | |
|---------------------------------|------------|--|--|
| **Signature of Reporting Person | Date | | |
| /s/ Ansbert Gadicke | 06/30/2004 | | |
| **Signature of Reporting Person | Date | | |

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 See Form 4 filed for MPM BioVentures III-QP, L.P. for additional members of this joint filing. The shares were sold as follows: 161 by MPM BioVentures III, L.P.
- (1) ("BVIII"); 2,395 by MPM BioVentures III-QP, L.P. ("BVIII QP"); 202 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BVIII KG"); 72 by MPM BioVentures III Parallel Fund, L.P. ("BVIII PF"); and 47 MPM Asset Management Investors 2003 BVIII LLC ("BVAM LLC"). MPM BioVentures III GP, L.P. ("BVIII GP") and MPM BioVentures III LLC ("BVIII LLC") are the direct and indirect partners of BVIII, BVIII QP, BVIII PF and BVIII KG.
- The shares are held as follows: 186,581 BVIII; 2,774,953 by BVIII QP; 234,518 by BVIII KG; 83,808 by BVIII PF; and 53,726 by BVAM LLC. Luke Evnin, Ansbert
- (2) Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon, III, Michael Steinmetz and Kurt Wheeler are the members of BVIII LLC and BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- (3) Pro rata distribution as follows: 83,958 by BVIII; 1,248,631 by BVIII QP; 105,523 by BVIII KG; 37,711 by BVIII PF; and 24,166 by BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- (4) The shares are held as follows: 102,623 by BVIII; 1,526,322 by BVIII QP; 128,995 by BVIII KG; 46,097 by BVIII PF; and 29,560 by BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- (5) Pro rata distribution from BVAM LLC as follows: 495 to AAG Peakham LLC ("AAG") of which Nicholas Galakatos is a manager, 7,847 to Luke Evnin; 3,910 to Ansbert Gadicke; 1,157 to Nicholas Galakatos; 1,968 to Michael Steinmetz; and 826 to Kurt Wheeler.
- The shares are held as follows: 102,623 by BVIII; 1,526,322 by BVIII QP; 128,995 by BVIII KG; 46,097 by BVIII PF; 29,560 by BVAM LLC; 495 by AAG; 7,847 by Luke (6) Evnin; 3,910 by Ansbert Gadicke; 1,157 by Nicholas Galakatos; 1,968 by Michael Steinmetz; and 826 by Kurt Wheeler. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.